Skip to main content
. 2020 Oct 5;11:4995. doi: 10.1038/s41467-020-18819-5

Fig. 5. Genomic subtypes of endometrioid ovarian carcinoma demonstrate distinct clinical behaviour.

Fig. 5

a Disease-specific survival based on TP53m and CTNNB1m status; labelled hazard ratio represents comparison of the TP53wt/CTNNB1m group with the TP53m group. HR for TP53wt/CTNNB1wt vs. TP53m = 0.37, 95% CI 0.18–78; HR for TP53wt/CTNNB1m vs. TP53wt/CTNNB1wt = 0.31, 95% CI 0.11–0.88. b Summary of the PRISTINE algorithm for molecular subtyping in endometrioid ovarian carcinoma. m mutant, wt wild-type, RD residual disease, WES whole exome sequencing, DSS disease-specific survival.